You are here

  • Home
  • Archive
  • Volume 13, Issue 1
  • Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry)

Article metrics

Article menu
Mental health
Protocol
Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry)

 

Online download statistics by month:

Online download statistics by month: January 2023 to October 2024

AbstractFullPdf
Jan 202389926
Feb 202310441020242
Mar 2023507478172
Apr 2023429385117
May 2023376356106
Jun 2023420391131
Jul 2023228209113
Aug 202324320594
Sep 2023374328193
Oct 2023304258124
Nov 2023325272126
Dec 2023312186131
Jan 2024336237172
Feb 2024322227153
Mar 2024326285182
Apr 2024393341221
May 2024443407197
Jun 2024299266155
Jul 2024355296184
Aug 2024322274195
Sep 2024401346172
Oct 2024554125
Total790369003211